320 related articles for article (PubMed ID: 36415537)
1. Real-World Outcomes and Prognostic Factors Among Patients with Advanced Non-Small Cell Lung Cancer and High PD-L1 Expression Treated with Immune Checkpoint Inhibitors as First-Line Therapy.
Ge W; Wu N; Jalbert JJ; Quek RGW; Liu J; Rietschel P; Pouliot JF; Harnett J; Hsu ML; Feliciano JL
Cancer Manag Res; 2022; 14():3191-3202. PubMed ID: 36415537
[TBL] [Abstract][Full Text] [Related]
2. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
3. Real-world data prognostic model of overall survival in patients with advanced NSCLC receiving anti-PD-1/PD-L1 immune checkpoint inhibitors as second-line monotherapy.
Julian C; Machado RJM; Girish S; Chanu P; Heinzmann D; Harbron C; Gershon A; Pfeiffer SM; Zou W; Quarmby V; Zhang Q; Chen Y
Cancer Rep (Hoboken); 2022 Oct; 5(10):e1578. PubMed ID: 35075804
[TBL] [Abstract][Full Text] [Related]
4. Very high PD-L1 expression as a prognostic indicator of overall survival among patients with advanced non-small cell lung cancer receiving anti-PD-(L)1 monotherapies in routine practice.
Shah M; Hubbard RA; Mamtani R; Marmarelis ME; Hennessy S
Pharmacoepidemiol Drug Saf; 2022 Oct; 31(10):1121-1126. PubMed ID: 35670103
[TBL] [Abstract][Full Text] [Related]
5. Characterizing the Shifting Real-World Treatment Landscape by PD-L1 Testing Status and Expression Level in Advanced Non-Small Cell Lung Cancer.
Ge W; Wu N; Quek RGW; Liu J; Pouliot JF; Dietz H; Jalbert JJ; Harnett J; Antonia SJ
Adv Ther; 2022 Oct; 39(10):4645-4662. PubMed ID: 35948845
[TBL] [Abstract][Full Text] [Related]
6. Analysis of Real-World Data to Investigate the Impact of Race and Ethnicity on Response to Programmed Cell Death-1 and Programmed Cell Death-Ligand 1 Inhibitors in Advanced Non-Small Cell Lung Cancers.
Ayers KL; Mullaney T; Zhou X; Liu JJ; Lee K; Ma M; Jones S; Li L; Redfern A; Jappe W; Liu Z; Goldsweig H; Yadav KK; Hahner N; Dietz M; Zimmerman M; Prentice T; Newman S; Veluswamy R; Wisnivesky J; Hirsch FR; Oh WK; Li SD; Schadt EE; Chen R
Oncologist; 2021 Jul; 26(7):e1226-e1239. PubMed ID: 33829580
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy beyond progression in patients with advanced non-small cell lung cancer.
Ge X; Zhang Z; Zhang S; Yuan F; Zhang F; Yan X; Han X; Ma J; Wang L; Tao H; Li X; Zhi X; Huang Z; Hofman P; Prelaj A; Banna GL; Mutti L; Hu Y; Wang J
Transl Lung Cancer Res; 2020 Dec; 9(6):2391-2400. PubMed ID: 33489801
[TBL] [Abstract][Full Text] [Related]
8. Association of Programmed Cell Death Ligand 1 Expression Status With Receipt of Immune Checkpoint Inhibitors in Patients With Advanced Non-Small Cell Lung Cancer.
Leapman MS; Presley CJ; Zhu W; Soulos PR; Adelson KB; Miksad RA; Boffa DJ; Gross CP
JAMA Netw Open; 2020 Jun; 3(6):e207205. PubMed ID: 32511721
[TBL] [Abstract][Full Text] [Related]
9. Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data.
Dudnik E; Moskovitz M; Rottenberg Y; Lobachov A; Mandelboim R; Shochat T; Urban D; Wollner M; Nechushtan H; Rotem O; Zer A; Daher S; Bar J;
Oncoimmunology; 2021 Jan; 10(1):1865653. PubMed ID: 33552685
[TBL] [Abstract][Full Text] [Related]
10. Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer.
Mountzios G; Samantas E; Senghas K; Zervas E; Krisam J; Samitas K; Bozorgmehr F; Kuon J; Agelaki S; Baka S; Athanasiadis I; Gaissmaier L; Elshiaty M; Daniello L; Christopoulou A; Pentheroudakis G; Lianos E; Linardou H; Kriegsmann K; Kosmidis P; El Shafie R; Kriegsmann M; Psyrri A; Andreadis C; Fountzilas E; Heussel CP; Herth FJ; Winter H; Emmanouilides C; Oikonomopoulos G; Meister M; Muley T; Bischoff H; Saridaki Z; Razis E; Perdikouri EI; Stenzinger A; Boukovinas I; Reck M; Syrigos K; Thomas M; Christopoulos P
ESMO Open; 2021 Oct; 6(5):100254. PubMed ID: 34481329
[TBL] [Abstract][Full Text] [Related]
11. First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis.
Mori K; Pradere B; Moschini M; Mostafaei H; Laukhtina E; Schuettfort VM; Sari Motlagh R; Soria F; Teoh JYC; Egawa S; Powles T; Shariat SF;
Eur J Cancer; 2021 Jul; 151():35-48. PubMed ID: 33962359
[TBL] [Abstract][Full Text] [Related]
12. 5-Year survival in Danish patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitor monotherapy.
Bjørnhart B; Mouritzen MT; Kristiansen C; Schytte T; Wedervang K; Pøhl M; Holmskov Hansen K
Acta Oncol; 2023 Aug; 62(8):861-870. PubMed ID: 37534770
[TBL] [Abstract][Full Text] [Related]
13. A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers.
Ayers KL; Ma M; Debussche G; Corrigan D; McCafferty J; Lee K; Newman S; Zhou X; Hirsch FR; Mack PC; Liu JJ; Schadt EE; Chen R; Li SD
BMC Cancer; 2021 Apr; 21(1):441. PubMed ID: 33882890
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab for Previously Treated, PD-L1-expressing Advanced NSCLC: Real-world Time on Treatment and Overall Survival.
Velcheti V; Chandwani S; Chen X; Piperdi B; Burke T
Clin Lung Cancer; 2020 Sep; 21(5):e445-e455. PubMed ID: 32376116
[TBL] [Abstract][Full Text] [Related]
15. Trends in real-world biomarker testing and overall survival in US patients with advanced non-small-cell lung cancer.
Wu N; Ge W; Quek RG; Gleeson M; Pouliot JF; Dietz H; Jalbert JJ; Harnett J; Antonia SJ
Future Oncol; 2022 Dec; 18(39):4385-4397. PubMed ID: 36656547
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer (NSCLC): a systematic literature review.
Wagner G; Stollenwerk HK; Klerings I; Pecherstorfer M; Gartlehner G; Singer J
Oncoimmunology; 2020 Jun; 9(1):1774314. PubMed ID: 32923134
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of PD-1/PD-L1 Inhibitors versus Chemotherapy in Lung Cancer with Brain Metastases: A Systematic Review and Meta-Analysis.
Yang X; Zeng Y; Tan Q; Huang Z; Jia J; Jiang G
J Immunol Res; 2022; 2022():4518898. PubMed ID: 35637793
[TBL] [Abstract][Full Text] [Related]
18. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of first-line PD-L1/PD-1 inhibitors in limited-stage small cell lung cancer: a multicenter propensity score matched retrospective study.
Xie J; Xu K; Cai Z; Chen M; Jiang Y; Ye J; Lin X; Lv T; Zhan P
Transl Lung Cancer Res; 2024 Mar; 13(3):526-539. PubMed ID: 38601454
[TBL] [Abstract][Full Text] [Related]
20. The efficacy of immune checkpoint inhibitors on low PD-L1 cervical cancer: A meta-analysis.
Chen W; Zhang N; He Z; Li Q; Wang Y; Lou W; Di W
Health Sci Rep; 2024 May; 7(5):e2069. PubMed ID: 38706804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
